ArticleJCI insight2025

Anti-PD-L1-IFN-α-adjuvanted HBsAg vaccine overcomes HBV immune tolerance through targeting both DCs and macrophages.

Chao-Yang Meng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.